C. F. Curran

发表

Streamlining the Information Retrieval Process in the Drug Information Department

Charles F. Curran, C. F. Curran, M. M. Buxton, 2001 .

Preparing a Clinical Site for a Clinical Investigator Inspection by the FDA

C. F. Curran, 1999 .

Extravasation of doxorubicin from vascular access devices.

C. F. Curran, J. Luce, 1990, Selective cancer therapeutics.

Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.

P. Narang, C. F. Curran, R. Reynolds, 1991, Cancer treatment reviews.

Ocular adverse reactions associated with adriamycin (doxorubicin).

C. F. Curran, J. Luce, 1989, American journal of ophthalmology.

A Multidrug Patient Assistance Program

C. F. Curran, 1991 .

A Progress Report: Drug Information from 1970 to 2000

C. F. Curran, 2000 .

Fluorouracil and palmar-plantar erythrodysesthesia.

C. F. Curran, J. Luce, 1989, Annals of internal medicine.

Acute overdoses of tacrolimus.

C. F. Curran, P. Blahunka, I. Lawrence, 1996, Transplantation.

Acute doxorubicin overdoses.

C. F. Curran, 1991, Annals of internal medicine.

Pemoline (Cylert®) In The Treatment Of Childhood Hyperkinesis

C. F. Curran, J. Bernstein, J. Page, 1974 .

Planning for Variations in Level of Inquiries Received by Drug Information Departments

C. F. Curran, 2001 .

Deceptive Inquiries Made to Drug Information Departments

Charles F. Curran, C. F. Curran, 2002 .

The Evolving Role of United States Industry-Based Drug Information Departments

C. F. Curran, 2003 .

Strategies for Increasing Drug Inquiry Response Efficiency

C. F. Curran, 2000 .